RVMD - RevMed Price Target Chart

Symbol and logo of brand Revolution Medicines Inc (RVMD)

Revolution Medicines controls the supply of rare biopharmaceutical components, ensuring the stability of tests. The market dynamics of the company's securities, where the indicator is 274.67, are presented below. The business relies on partnerships with industry behemoths to develop combination therapies. Simultaneously, the firm minimizes risks by developing a broad spectrum of drugs against various forms of tumors, reducing dependence on the outcome of any single study.

RVMD Revolution Medicines Inc: Analyst Consensus Forecast in the range 07/04/2022 - 11/12/2026
Original product of RevMed

Investors assess the business quality of Revolution Medicines (RVMD) through the resilience of fundamental value against market volatility. The weighted average of leading analysts' price targets filters out short-term fluctuations to determine fair capitalization potential. For the biotech sector, this metric reflects the probability of clinical trial success and drug commercialization. Inelastic demand for innovation renders such forecasts independent of economic cycles. The dynamics of the consensus target within analyst coverage serve as an objective vector for long-term growth.

Competing companies

ONC (beigene.com) - Fair Value Consensus|Halozyme - Consensus Target|Ascentage Pharma Group International - Price Target Chart|CGON - Price Target Chart|UroGen Pharma Corp (URGN) - Consensus Target|BCAX: Analyst Consensus Forecast|Broker Consensus Forecast PSNL|ERAS (Erasca) - Analyst Consensus Forecast|Consensus Target Delcath Systems Inc (DCTH)|Analyst Consensus Forecast YMAB|Analyst Consensus Forecast Aura Corp (AURA)|Price Target Chart Candel Therapeutics, Inc. CADL|ARAY: Broker Consensus Forecast|SELLAS Life Sciences Group Inc. - Analyst Consensus Forecast|Actuate Therapeutics Inc. (ACTU) - Consensus Target|CTOR: Analyst Consensus Forecast|Average Forecast Price TuHURA Biosciences (HURA)|Price Target Chart Protara Therapeutics|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Price Target Chart Tempest Therapeutics (TPST)|XLO (xiliotx.com) - Fair Value Consensus|Analyst Consensus Forecast RENB (Renovaro)|Mural Oncology PLC (MURA) - Average Forecast Price|KAPA: Consensus Target|OKUR: Price Target Chart|w2.cytomed.sg (GDTC) - Price Target Chart|Average Forecast Price Curis (CRIS)|Price Target Chart Apollomics Inc.|Price Target Chart THAR|Consensus Target ADVB (Advanced Biomed Inc)|Analyst Consensus Forecast Genprex Inc (GNPX)|Calidi Biotherapeutics, Inc. - Consensus Target|Analyst Forecast Prices SBFM (Sunshine Biopharma Inc.)|Xenetic Bio - Analyst Consensus Forecast|Analyst Median Target Salarius Pharmaceuticals Inc SLRX|Purple Biotech Corp (PPBT) - Price Target Chart|Average Forecast Price American Oncology Network, Inc. (AONC)|Price Target Chart BeiGene, Ltd.|Broker Consensus Forecast CKPT (checkpointtx.com)|Consensus Target ELEV (Elevation Oncology, Inc.)|ICAD (icadmed.com) - Fair Value Consensus|Price Target Chart Ikena Oncology IKNA|NTBL - Consensus Target|Viracta - Analyst Consensus Forecast|Average Forecast Price morphosys.com|NAYA: Analyst Consensus Forecast|Broker Consensus Forecast AAPGV